Fair Value Measurements (Tables)

12 Months Ended

Jun. 30, 2026

Notes Tables

Schedule of information by level for financial assets and liabilities that are measured at fair value on a recurring basis

The following tables provide information by level for financial assets and liabilities that are measured at fair value on a recurring basis (in thousands):


		* *	Total
			carrying
			value as of			Fair Value Measurements Using
	Balance Sheet Location		June 30,			Inputs Considered as
			2026			Level 1			Level 2			Level 3
Assets
Exchange traded securities⁽¹⁾	Other current assets		$	767		$	767		$	—		$	—
Notes receivable⁽²⁾	Other current assets			3,913			—			—			3,913
Notes receivable⁽²⁾	Other assets			7,560			—			—			7,560
Total assets			$	12,240		$	767		$	—		$	11,473

Liabilities
Derivatives designated as hedging instruments - net investment hedge	Other long-term liabilities		$	14,712		$	—		$	14,712		$	—
Total liabilities			$	14,712		$	—		$	14,712		$	—

(1)	Exchange traded securities received from the buyer in the sale of Exosome Diagnostics.

(2)	Notes receivable relate to the divestiture of our businesses held-for-sale.


		* *	Total
			carrying
			value as of			Fair Value Measurements Using
	Balance Sheet Location		June 30,			Inputs Considered as
		* *	2025			Level 1		* *	Level 2		* *	Level 3
Assets
Derivatives designated as hedging instruments - cash flow hedges	Other current assets		$	2,843		$	—		$	2,843		$	—
Note receivable⁽¹⁾	Other current assets			3,078			—			—			3,078
Note receivable⁽¹⁾	Other assets			2,184			—			—			2,184
Total assets			$	8,105		$	—		$	2,843		$	5,262

Liabilities
Derivatives designated as hedging instruments - net investment hedge	Other long-term liabilities		$	18,034		$	—		$	18,034		$	—
Total liabilities			$	18,034		$	—		$	18,034		$	—

⁽¹⁾	Notes receivable relates to the divestiture of our business held-for-sale.

Schedule of reconciliation of the notes receivable measured on a recurring basis using significant unobservable inputs (Level 3)

The following table presents a reconciliation of the notes receivable measured on a recurring basis using significant unobservable inputs (Level 3) (in thousands):


		June 30,
		2026			2025
Beginning balance		$	5,262		$	7,051
Additions			9,000			—
Payments received			(1,973)			(1,789)
Changes in fair value included in earnings			(816)			—
Ending balance		$	11,473		$	5,262

Schedule of contractual amounts of the outstanding instruments

The following table presents the contractual amounts of the Company’s outstanding instruments (in millions):


			* *	June 30,
Instruments		Designation	* *	2026			2025
Forward starting swaps⁽¹⁾		Cash flow hedge		$	—		$	200
Cross-currency swap⁽²⁾		Net investment hedge			130			140

(1)	In May 2021, the Company entered into a forward starting swap designated as a cash flow hedge on forecasted debt based on $200 million of notional principal. The effective date of the swap was November 2022 and matured in November 2025. No cash flow hedges were entered into as of June 30, 2026.

(2)

In July 2023, the Company entered into a pay-fixed rate, receive-fixed rate cross-currency swap contract with a total notional amount of $150 million that was designated as a hedge to lock in the Swiss franc (CHF) rate for a portion of the Company’s CHF net investment in its Lunaphore subsidiary in Switzerland. The objective of the hedge is to protect the net investment in the Company’s CHF-denominated operations against changes in the spot exchange rates, on a pre-tax basis. The hedging instrument has four interim settlement dates, which will reduce the notional on the hedging instrument by $10 million at each interim date, and will reduce the notional to $110 million at maturity.

Schedule of pretax amount of the gains and losses on our hedging instruments and the classification of those gains and losses

The pretax amount of the gains and losses on our hedging instruments and the classification of those gains and losses within the Consolidated Financial Statements for the years ended June 30, 2026, 2025 and 2024 were as follows (in thousands):


		(Gain) Loss Recognized in Accumulated Other Comprehensive Loss
	* *	Year Ended
		June 30,
	* *	2026			2025			2024
Cash flow hedges
Forward starting swaps		$	4,702		$	11,530		$	12,632
Net investment hedges
Cross-currency swap			(557)			14,301			4,015
Total		$	4,145		$	25,831		$	16,647


		Gain Reclassified into Income
	* *	Year Ended
		June 30,									Income Statement
	* *	2026			2025			2024			Classification
Cash flow hedges
Forward starting swaps		$	(2,839)		$	(8,448)		$	(10,317)		Interest expense
Net investment hedges
Cross-currency swap			(2,592)			(2,761)			(3,210)		Interest expense
Total		$	(5,431)		$	(11,209)		$	(13,527)

Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.

+ References + Details